Journal Article

Immune Responses to Human Immunodeficiency Virus (HIV) Type 1 Induced by Canarypox Expressing$HIV-1_mn$gpl20,$HIV-1_SF2$Recombinant gp120, or Both Vaccines in Seronegative Adults

Mascola, John, Hsieh, Ray-Hahn, Matthews, Thomas J., Xu, Serena, Clements-Mann, Mary Lou, Walker, Mary Clare, Zolla-Pazner, Susan, Schwartz, David, Graham, Barney S., Weinhold, Kent, Fast, Patricia, Mestecky, Jiri, Corey, Lawrence, Tartaglia, James, Paoletti, Enzo, Dolin, Raphael, Belshe, Robert, Wright, Peter F., Gorse, Geoffrey J., Siliciano, Robert, Duliege, Anne-Marie, Sinangil, Faruk, Jackson, Susan, McElrath, M. Juliana, Stablein, Don, Keefer, Michael C., Excler, Jean-Louis

1998

Overview

A safety and immunogenicity trial was conducted in vaccinia-immune and vaccinia-naive human immunodeficiency virus (HIV)-uninfected adults who were randomized to receive 10⁶ or 10⁷$TCID_50$of canarypox (ALVAC) vector expressing$HIV-I_{MN}$gp160 or$10^5.5$ $TCID_50$of ALVAC-rabies virus glycoprotein control at 0 and 1 or 2 months and ALVAC-gp160 or 50 µg of$HIV-1_{SF2}$recombinant (r) gpl20 in microfluidized emulsion at 9 and 12 months; others received rgp120 at 0, 1, 6, and 12 months. All vaccines were well-tolerated. Neither vaccinia-immune status before vaccination nor ALVAC dose affected HIV immune responses.$HIV-I_{MN}$and$HIV-1_SF2$neutralizing antibodies were detected more often (100%) in ALVAC-gp160/rgp120 recipients than in recipients of ALVAC-gp160 (<65%) or rgp120 (89%) alone. ALVAC-gp160/rgp120 also elicited more frequent HIV V3-specific and fusion-inhibition antibodies, antibody-dependent cellular cytotoxicity, lymphoproliferation, and cytotoxic CD8⁺ T cell activity than did either vaccine alone. Trials with ALVAC expressing additional HIV components and rgp120 are underway.

• Publisher: University of Chicago Press
• Subject: AIDS / Antibodies / Antigens / HIV / HIV 1 / Immunization / Major Articles / Neutralizing antibodies / T lymphocytes / Vaccination / Vaccinia